1. Introduction
===============

Enhanced recovery after surgery (ERAS) is a clinical-based multi-model care pathway widely used in the world. It has been proved effective in reducing the length of hospital stay (LOS) and the incidence of complication and promoting patients rehabilitation after surgery.^\[[@R1]\]^ In recent years, ERAS has been gradually applied to various types of clinical surgeries, especially colorectal surgery .^\[[@R2],[@R3]\]^

ERAS program is an integrative and multidisciplinary innovation, in which traditional clinical pathway is changed.^\[[@R4]\]^ ERAS aims to reduce trauma and stress response of patients to promote recovery via multi-model, multi-channel, and integrative approaches ahead, during and after operation.^\[[@R5]\]^ Its main strategy is to optimize the perioperative treatment through surgery, anesthesia, nursing, and other multi-disciplinary cooperation.^\[[@R6]\]^ The most important perioperative measures include 5 entries: multi-model analgesic regimen to avoid or reduce the use of opioid analgesics; avoidance or reduction in using nasogastric tube; early postoperative bed activity; early recovery of oral intake and drinking water; avoidance of too much or too little intravenous infusion.^\[[@R7],[@R8]\]^

To date, the study on the application of ERAS to hepatectomy is very rare. To empirical knowing, the incidence of complication after hepatectomy is high (15%--48%), and the LOS in hospital is long.^\[[@R9]\]^ These problems can be solved by ERAS application. Thus, it is highly appreciated. So far, ERAS program has been proved cost-effective for colorectal surgery in China.^\[[@R10]\]^ The main purpose of this study was to assess the primary clinical efficacy and cost-effectiveness of ERAS after hepatectomy for Chinese Han population.

2. Methods
==========

ERAS has been tentatively applied after hepatectomy in the Affiliated Hospital of Qingdao University in December, 2016, where ERAS protocol has been explored in gastrointestinal surgery in 2011 with a wealth of experience. We followed the protocols including counseling and education (physicians and nurses), fasting (provision of oral nutrition), no routine bowel preparation, balanced intravenous fluids, no routine use drain tube, epidural anesthesia, intraoperative warm-air body heating, multi-model anesthesia, normal diet, and more mobilization out of bed (Table [1](#T1){ref-type="table"}). Our ERAS teams have hepatectomy surgeries based on ERAS guidelines published by Chinese surgical experts and European ERAS association.^\[[@R11]\]^ This study was a retrospective survey, and the data were collected from previous medical records and did not involve patient consent. It was approved by the ethics committee of The Affiliated Hospital of Qingdao University.
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2.1. Patient grouping
---------------------

A total of 200 patients with primary hepatocellular carcinoma (HCC) who received hepatectomy from July 2016 to June 2017 participated in this study. All patients were given detailed information after admission and voluntarily participated in the study with full knowledge. All patients were divided into 2 groups by establishing 2 retrospective queues based on the beginning of ERAS: Pre-ERAS, 121 consecutive patients without experiencing ERAS for hepatectomy from July to Dec 2016; ERAS, remaining 79 consecutive patients who received ERAS for hepatectomy from Jan to Jul 2017.

2.2. Perioperative parameters
-----------------------------

Perioperative parameters of the measurement involved three parts, including preoperative, intraoperative, and postoperative. The emphasis was focused on postoperative parameters relating to the LOS, complication, and readmission. The LOS was calculated according to the time from the first operation to discharge. Complication was graded to minor, major and mortal according to the Dindo--Clavien classification.^\[[@R12]\]^ The readmission was the rate of second hospital admission after 30 days.^\[[@R13],[@R14]\]^ The basic demographic and clinical differences were also measured.

2.3. Cost analysis
------------------

A comprehensive analysis of patients' real costs was performed with the method early described by Joliat et al.^\[[@R15]\]^ Cost, specifically of the intraoperative and pre/postoperative, was compared based on the information obtained from hospital information system. Intraoperative cost mainly included the expense for disposable material, anesthesia and operating room use. Preoperative and postoperative cost covered the expense in intensive care unit (ICU), medical care, nursing care, medication, blood, laboratory, radiology, inspection, pathology, and housing among others.^\[[@R16]\]^ The details of the cost were shown in Table [2](#T2){ref-type="table"}.
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2.4. Cost-minimization analysis
-------------------------------

Cost-minimization analysis was carried out, aiming to assess the cost saving per patient. The saving was measured by subtracting the ERAS cost from the pre-ERAS cost. The cost-minimization was realized by taking the minimum among all programs.^\[[@R17],[@R18]\]^

2.5. Cost-effectiveness analysis
--------------------------------

Average cost-effectiveness ratio, that is, the cost of producing one effect each. This present analysis was obtained by calculating the average cost per patient to the overall cure rate ratio. We calculated and compared using C/E.

Incremental cost-effectiveness ratio, that is, the ERAS group and pre-ERAS group were compared, the ratio of cost change to effectiveness change when taking different treatments. We calculated and compared using incremental cost-effectiveness ratio (ICER). 

2.6. Statistical analysis
-------------------------

Either T or Mann--Whitney *U* test was used for continuous variables, *χ*^*2*^ test was used for discrete variables and Wilcoxon rank sum test was used to non-normal distribution data. Statistical analysis was performed using SPSS 21.0 (IBM, Armonk, NY).

3. Results
==========

A total of 200 patients with hepatectomy have participated this program at the Affiliated Hospital of Qingdao University, 121 in the pre-ERAS group and 79 were in the ERAS group. All patients were treated by the same group of physicians. Demographics and surgical characteristics of the 2 groups were shown in Table [3](#T3){ref-type="table"}.
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Patient demographics and surgical characteristics.

![](medi-97-e11957-g004)

3.1. Perioperative outcome
--------------------------

The number of laparoscopic surgery was 54 for pre-ERAS group and 39 for ERAS group, and no significant difference existed between 2 groups (*P* = .737). Pre-ERAS group were similar to ERAS group in the mean operation time and the mean anesthesia time. The mean operation time was 175 minutes versus 168 minutes (pre-ERAS vs ERAS; *P* = .417). Similarly, the mean anesthesia time was 234 minutes versus 220 minutes (pre-ERAS vs ERAS; *P* = .176). The blood loss was 205 mL for Pre-ERAS and 167 mL for ERAS group, similar with each other (*P* = .293).

The mean postoperative LOS was significantly longer in pre-ERAS group than in ERAS group (8.06 vs 5.81 d, *P* = .000), whereas the ICU stay of ERAS group was similar to that of pre-ERAS group (1.78 vs 1.93 d; *P* = .429). The complication rate was significantly different between 2 groups, 15 cases in pre-ERAS group, including 6 cases of bile leakage, 1 case of ascites, 3 cases of incision infection and 1 case of hepatic failure, and 4 cases in ERAS group, 2 cases of bile leakage, 1 case of ascites, 1 case of hepatic failure. Pre-ERAS group were also significantly different from ERAS group in complication (*P* = .040) and readmission (*P* = .033) (Table [4](#T4){ref-type="table"}).
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3.2. Cost analysis
------------------

Based on ERAS, the mean cost was 51556.18 Yuan (7835.05 US dollars) per patient, lower than 60554.66 Yuan (9202.56 US dollars) (*P* = .000) of pre-ERAS. The preoperative and postoperative cost of ERAS was 27566.79 Yuan (4190.50 US dollars), also lower than that of pre-ERAS 35315.83 Yuan (5368.45 US dollars) (*P* = .000). There was significant difference between 2 groups in nursing care, medication, laboratory, pathology, and housing costs (*P* \< .05). The lower cost of ERAS group indicated that the implementation of ERAS protocol efficiently reduced the costs in treatment, drug, laboratory, and inspection among others (Table [5](#T5){ref-type="table"}).
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3.3. Cost-minimization analysis
-------------------------------

The difference of mean total cost per patient between ERAS and pre-ERAS groups was 8998.48 Yuan (1367.51 US dollars), demonstrating that the application of ERAS efficiently reduced patients' hospitalization cost and saved 8998.48 Yuan (1367.51 US dollars) for each patient (Table [6](#T6){ref-type="table"}).
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Cost-minimization analysis.
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3.4. Cost-effectiveness analysis
--------------------------------

We assessed the impact of ERAS on patients' health services utilization within 30 days of discharge by comparing pre-ERAS groups and ERAS groups using the data from the inpatient department of hospital. The cure rate is the number of cures per 100 patients treated by the doctor. It can also be defined as the probability that a disease can be cured. It was showed that the cure rate of patients with hepatectomy was significantly increased after the implementation of ERAS. (82.64% vs 91.14%) (Table [7](#T7){ref-type="table"}). 
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Cost-effectiveness analysis was necessary to further evaluate the advantages and disadvantages of the 2 surgical regimens. The results showed that the cost-effectiveness ratio (C/E) of the pre-ERAS group is 73.31 thousand Yuan (11.19 thousand US dollars) and that of the ERAS group is 56.59 thousand Yuan (8.64 thousand US dollars) ( Table [8](#T8){ref-type="table"}).
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Cost-effectiveness ratio.
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In incremental analysis that allows all variables to vary simultaneously, we analyzed 2 scenarios: incremental cost; incremental effectiveness. Table [9](#T9){ref-type="table"} showed the cure rate increased by 1% and cost reduced by 1058 Yuan with the implementation of ERAS.
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Incremental cost-effectiveness ratio.
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We estimated health care costs/savings associated with effectiveness calculated in the first step for the pre-ERAS and ERAS patients using a economic methodology model-ling technique (Figs. [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). In Figure [1](#F1){ref-type="fig"}, the Y axis represents the effectiveness, which indicates an effect (cure rate) of 0.826 in pre-ERAS and 0.911 in ERAS; in Figure [2](#F2){ref-type="fig"}, the Y axis represents the cost, which indicates a cost of 60.55 thousand Yuan in pre-ERAS and 51.56 thousand Yuan in ERAS. It can be seen that the cost-effectiveness of ERAS is significantly better than that of the pre-ERAS group.

![Effectiveness-analysis.](medi-97-e11957-g012){#F1}

![Cost-analysis.](medi-97-e11957-g013){#F2}

4. Discussion
=============

China has the heaviest population of patients with liver disease in the world, and a large number of patients with liver cancer. There were about 700,000 cases of new liver cancer around the world each year, of which more than one half occurred in China. However, the benefits of introducing the ERAS program for Chinese Han patients with hepatectomy were not clear.

Our study showed that the Los of ERAS group is 5.81 days, which is shorter than the LOS in Pre-ERAS group (8.06 d). This finding was consistent with the study of Dai Shida et al.^\[[@R19]\]^ As reported, the median LOS of the ERAS group (7 vs 10 d) was shorter with a 3-day reduction for colorectal cancer. In terms of the return on investment, the application of ERAS in hepatectomy would save 8998.48 Yuan (1367.51 US dollars) per patient in return, which was consistent with the results of six controlled trials, a meta-analysis wrote by Mariëlle.^\[[@R20]\]^

In our study, different cost was observed between the pre-ERAS and ERAS groups, in which some items cost had risen and the other had fallen. The biggest saving was in medication, especially after the application of ERAS to hepatectomy. The difference between use and not use was statistically significant (*P* = .004). The reduction in medication cost was due to a reduction in drug use, which was attributed to the combination of the standard clinical pathway and the standard nursing care in the ERAS program.^\[[@R21],[@R22]\]^ In addition, the application of ERAS was helpful for reducing postoperative complications.^\[[@R23]\]^ So there were a fewer and fewer patients taking drugs to cure postoperative complications. These findings were consistent with professor Joliat\'s research: less postoperative medication was used related to ERAS.^\[[@R15]\]^ All of these results support the conclusion that ERAS can lead to a reduction in medication cost.

The second statistically significant gain in ERAS group was the reduction in laboratory cost (*P* = .003). The number of laboratory diagnostic items reduced, which could be due to the reduced postoperative complications, the standardized clinical pathway, the postoperative nursing care, and the combination of all measures in ERAS.^\[[@R24]--[@R26]\]^ However, our findings suggested that anesthesia and operating room cost was similar in 2 groups. According to the previous studies, anesthesia and operating room cost was responsible for the second main absolute gain (£ 2045) in the ERAS group, which was in line with Labgaa\'s results.^\[[@R27]\]^ Our study showed that ERAS played an important role in decreasing the economic burden on patients, and many item costs had fallen significantly, including nursing care, medication, laboratory, pathology, and housing.

However, anesthesia and operating room costs rose in ERAS group. The anesthesia methods were different between ERAS group and pre-ERAS group: epidural anesthesia in ERAS is better than intravenous anesthesia in pre-ERAS for patients. The cost of anesthesia consists of basic anesthesia costs and anesthetic drug costs. The basic anesthesia costs were essentially the same in both groups, while the cost of anesthetic drugs was relatively high in ERAS group. There was no significant difference in operating time between the 2 groups during the operation.

Regarding to the composition of the cost, we found that the disposable materials cost and the medication cost were the largest proportion. According to the foreign studies, however, these 2 costs accounted for a small proportion.^\[[@R10]\]^ This is probably due to the fact that the former was mainly depended on imports. On the contrary, the proportion of ICU care cost, medical care cost, and nursing care cost were lower in China. Different countries have different medical habits and environment. The charges of medical work mainly base on the patient\'s conditions.^\[[@R28],[@R29]\]^ At present, all these costs are constantly adjusted, so that it really reflects the medical value in China.

Previous studies showed that systematic evaluation of ERAS was safe and feasible, it benefited patients mainly in a shorter Los and relatively lower cost.^\[[@R30]\]^ A study by Bernard et al^\[[@R31]\]^ found that gynecologic tumor surgery significantly reduced the Los (5 vs7 d, *P* \< .001). This result supported the view that ERAS program could achieve clinical promotion.^\[[@R32]\]^ The average LOS in Chinese Han patients with colorectal surgery could be reduced by 2.5 days and the risk of postoperative complications was reduced by 47%, which were found in a study by Danlong Feng. A fewer patients were readmitted to the hospital for treatment, and none of the patients died in our study.

Recent systematic reviews on ERAS showed that it was cost-effective. In terms of Nguyen\'s study, he referred that every \$ 1 spent in ERAS would bring \$ 3.8 (range, \$ 2.4--\$ 5.1) in return.^\[[@R33]\]^ Nevertheless, our present study suggests a detailed analysis of the actual cost of ERAS in liver surgery. Therefore, ERAS program should be gradually extended from tertiary hospitals to secondary hospitals in China in order to solve China\'s medical problems, "proper health care is difficult to get" and "proper health care is expensive."

However, this study also has some limitations. We only focused on the implementation of ERAS in the Affiliated Hospital of Qingdao University and the sample may not be broadly representative. More studies on the use of ERAS in hepatectomy are needed, especially randomized prospective studies.

5. Conclusion
=============

This study demonstrated that the initial phase of the ERAS implementation program for hepatectomy surgery in the Affiliated Hospital of Qingdao University was safe and effective for Chinese Han population. It eventually enhanced the clinical healing rate. The benefits from such programs including a reduction of the LOS, complications, and readmission rates. So each patient has access to better medical service. It effectively relieved the financial burden of patients. The benefits from such programs including a reduction of the hospitalization cost, especially in medication cost. So each patient can afford diseases. Cost savings was different between our present study and other studies from foreign countries on ERAS applications. It\'s mainly due to different medical habits and environment in different countries. The total savings or return on investment may be more substantial when ERAS is spread to other clinical departments. However, this study also has some limitations. We only focused on the implementation of ERAS in the Affiliated Hospital of Qingdao University and the sample may not be broadly representative.
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